Moreover, a recent study reported that SFKs are frequently involved in promoting inhibitor-resistant CML, even after successful inhibition of BCR-Abl activity [25]. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.